Global Insulin Market Growth 2025-2031

The global Insulin market size is predicted to grow from US$ million in 2025 to US$ million in 2031; it is expected to grow at a CAGR of %from 2025 to 2031.

Insulin is used to treat type 1 diabetes (condition in which the body does not produce insulin and therefore cannot control the amount of sugar in the blood). It is also used to treat people with type 2 diabetes (condition in which the body does not use insulin normally and, therefore, cannot control the amount of sugar in blood) who need insulin to control their diabetes. Nowadays, Insulin as an important drug is widely used to treat diabetes.

The major players in China Insulin market include Novo Nordisk, Eli Lilly, etc. The top 2 players occupy about 60% shares of the whole market. Tianjin and Jiangsu are main markets, they occupy about 60% of the whole market. Regular Human Insulin is the main type, with a share over 60%. Long Acting and Intermediate Acting are the main applications, which holds a share about 70%.

LP Information, Inc. (LPI) ' newest research report, the “Insulin Industry Forecast” looks at past sales and reviews total world Insulin sales in 2024, providing a comprehensive analysis by region and market sector of projected Insulin sales for 2025 through 2031. With Insulin sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Insulin industry.

This Insight Report provides a comprehensive analysis of the global Insulin landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Insulin portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Insulin market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Insulin and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Insulin.

This report presents a comprehensive overview, market shares, and growth opportunities of Insulin market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:
Animal Insulin
Regular Human Insulin
Insulin Analogue

Segmentation by Application:
Short Acting
Intermediate Acting
Long Acting
Pre-Mix Insulin

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Novo Nordisk
Eli Lilly
Sanofi-Aventis
Tonghua Dongbao
Ganlee
United Laboratory
Jiangsu Wanbang

Key Questions Addressed in this Report

What is the 10-year outlook for the global Insulin market?

What factors are driving Insulin market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Insulin market opportunities vary by end market size?

How does Insulin break out by Type, by Application?

Please note: The report will take approximately 2 business days to prepare and deliver.